title: JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.
abstract: Immature platelets (IPFs), which are hemostatically more active than mature platelets, have been found elevated in essential thrombocythemia and polycythemia vera, 2 myeloproliferative neoplasms (MPN) characterized by an increased risk of thrombosis. It is not known whether the IPF levels are influenced by pathogenetic factors, including JAK2V617F mutational status, or by treatment regimen. To address this point, in 46 essential thrombocythemia and 38 polycythemia vera consecutive patients, we measured IPF and correlated the results to JAK2V617F mutation and myelosuppressive treatment with hydroxyurea. This analysis provides 2 new elements regarding IPF and MPN. The first finding is that the JAK2V617F mutation is linked to the quantity of IPF in patients with MPN, which might contribute to the prothrombotic phenotype in these patients. The second finding is that IPF is susceptible to myelosuppressive treatment, which may additionally explain the favorable effect of hydroxyurea therapy on MPN outcome as well as the associated thrombotic risk.
authors.affiliation: Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti di Bergamo, Bergamo, Italy.
authors.forename: Marina
authors.initials: M
authors.lastname: Panova-Noeva
authors.forename: Marina
authors.initials: M
authors.lastname: Marchetti
authors.forename: Sabrina
authors.initials: S
authors.lastname: Buoro
authors.forename: Laura
authors.initials: L
authors.lastname: Russo
authors.forename: Annamaria
authors.initials: A
authors.lastname: Leuzzi
authors.forename: Guido
authors.initials: G
authors.lastname: Finazzi
authors.forename: Alessandro
authors.initials: A
authors.lastname: Rambaldi
authors.forename: Cosimo
authors.initials: C
authors.lastname: Ottomano
authors.forename: Hugo
authors.initials: H
authors.lastname: Ten Cate
authors.forename: Anna
authors.initials: A
authors.lastname: Falanga
mesh_terms: D001792:Blood Platelets / Q000473:pathology*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D053614:Janus Kinase 2 / Q000235:genetics* / Q000502:physiology; D020125:Mutation, Missense; D010641:Phenotype; D010976:Platelet Count; D017354:Point Mutation; D011087:Polycythemia Vera / Q000097:blood* / Q000150:complications / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D013920:Thrombocythemia, Essential / Q000097:blood* / Q000150:complications / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D019851:Thrombophilia / Q000209:etiology*; D034061:Thrombopoiesis / Q000187:drug effects
chemical_list: C507924:JAK2 protein, human; D053614:Janus Kinase 2; D006918:Hydroxyurea